Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders-Reference-Cited by-同舟云学术

Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders

Published:2023 Issue:11 Volume:14 Page:2342-2347
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Chu Tifany¹,Karmakar Joy¹,Haggie Peter M.²,Tan Joseph-Anthony²,Master Riya¹,Ramaswamy Keerthana¹,Verkman Alan S.²,Anderson Marc O.³,Cil Onur¹^ORCID

Affiliation:

1. Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA

2. Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

3. Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA, USA

Abstract

This study reports identification of selective isoxazolopyrimidine inhibitors of intestinal anion exchanger SLC26A6 (PAT1) with improved potency and good in vivo efficacy. PAT1 inhibitors are novel drug candidates for intestinal diseases.

Funder

Cystic Fibrosis Foundation

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D3MD00302G

Reference23 articles.

1. Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Other Gastrointestinal Pathology in the Cystic Fibrosis Patient

2. Gastrointestinal Manifestations of Cystic Fibrosis

3. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis

4. SLC transporters: structure, function, and drug discovery

5. The SLC26 gene family of anion transporters and channels